Sjogren’s syndrome is a chronic autoimmune disease that mainly affects the body’s exocrine glands, particularly those producing saliva and tears. The immune system mistakenly attacks healthy glandular tissue, triggering inflammation that leads to reduced secretions. As a result, patients commonly experience dry eyes and dry mouth, also known as sicca symptoms. The condition may also involve mucosal surfaces in the respiratory tract, nose, throat, and in women, the vaginal area.

Epidemiology Overview (2020–2034, 7MM)

The epidemiological analysis of Sjogren’s syndrome includes:

Diagnosed prevalent population

Gender-based prevalence

Primary vs. secondary Sjogren’s syndrome

Severity levels (mild vs. moderate/severe)

Autoantibody-positive patients (anti-Ro/SSA, anti-La/SSB)

Number of patients undergoing treatment

Key Epidemiological Insights

In 2023, the United States reported approximately 1.5 million diagnosed cases of Sjogren’s syndrome, with numbers expected to rise in the coming years. The majority of these were autoantibody-positive, particularly those carrying anti-Ro/SSA and anti-La/SSB markers.

Across the 7MM (US, EU4, UK, and Japan), mild cases were more common than moderate or severe forms. In Europe, female prevalence dominated, especially in the UK, which recorded the highest diagnosis rate among the EU4 and UK.

Treatment-wise, the US led with the highest number of treated patients, while Japan had the fewest, with about 54,000 treated cases in 2023. Treatment uptake is projected to increase significantly by 2034. More detailed insights are available in this Sjogren’s Syndrome Market Analysis.

Market Landscape

As of 2023, the Sjogren’s Syndrome market in the 7MM was valued at approximately USD 2 billion, reflecting both growing diagnosis and increased awareness.

Market Drivers

Enhanced diagnostic approaches and clinical understanding are enabling better disease management.

Research into genetic, epigenetic, and environmental triggers is paving the way for next-gen therapeutics.

Market Barriers

There is currently no disease-modifying treatment, with existing therapies focused on symptom control.

More robust and targeted clinical trials are needed, especially for systemic symptoms and chronic fatigue.

For further details, refer to this Sjogren’s Syndrome Infographic Insight.

Promising Pipeline Therapies

Several innovative treatments are advancing through clinical development, including:

Dazodalibep

OXERVATE

VAY736

CFZ 533

RSLV-132

SOTYKTU

Nipocalimab

And more emerging therapies on the horizon

These therapies aim to address not only dryness but also systemic manifestations, offering a more holistic approach to disease management. For the latest drug developments and trial updates, check the full market forecast.

Key Industry Players

Major pharmaceutical and biotech companies actively contributing to the Sjogren’s Syndrome treatment landscape include:

GlaxoSmithKline

Pfizer

AbbVie

Eli Lilly

Novartis

Bristol Myers Squibb

Sanofi

AstraZeneca

Roche

Biogen

Resolve Therapeutics

VIELABIO

Daiichi Sankyo

TearSolutions

RemeGen

Advanz Pharma

Celgene

Genentech

Johnson & Johnson

Takeda

Gilead Sciences

Amgen

Merck & Co.

Vertex Pharmaceuticals

Bayer AG

Boehringer Ingelheim

And others continuing to expand their pipelines

To explore these companies and their emerging assets in greater detail, visit the Sjogren’s Syndrome Market Infographic.